CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 107 enrolled
Drug / intervention
phenethyl isothiocyanate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00691132
NCT00691132Phase 2Completed
CompareCT.gov

Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers

University of Minnesota·interventional·Posted Jun 5, 2008·Updated May 12, 2017

In Brief

A Phase 2 clinical trial evaluating phenethyl isothiocyanate and placebo for Lung Cancer and Tobacco Use Disorder. Completed, enrolled 107 participants across 1 site.

Detailed Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of phenethyl isothiocyanate may prevent lung cancer in people who smoke cigarettes. PURPOSE: This randomized clinical trial is studying phenethyl isothiocyanate to see how well it works in preventing lung cancer in smokers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Tobacco Use Disorder
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 5, 2008
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.1 years ago

Interventions

phenethyl isothiocyanatedrug

Given orally

placeboother

Given orally